CN110269859B - Application of quinoxaline-1, 4-dioxide compound in resisting toxoplasma gondii infection - Google Patents
Application of quinoxaline-1, 4-dioxide compound in resisting toxoplasma gondii infection Download PDFInfo
- Publication number
- CN110269859B CN110269859B CN201910400204.7A CN201910400204A CN110269859B CN 110269859 B CN110269859 B CN 110269859B CN 201910400204 A CN201910400204 A CN 201910400204A CN 110269859 B CN110269859 B CN 110269859B
- Authority
- CN
- China
- Prior art keywords
- toxoplasma gondii
- toxoplasma
- quinoxaline
- resisting
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 201000005485 Toxoplasmosis Diseases 0.000 title claims abstract description 13
- -1 quinoxaline-1, 4-dioxide compound Chemical class 0.000 title claims description 24
- 241000223997 Toxoplasma gondii Species 0.000 claims abstract description 54
- 239000003814 drug Substances 0.000 claims description 57
- 230000000694 effects Effects 0.000 claims description 23
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 239000001257 hydrogen Substances 0.000 claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 230000000120 cytopathologic effect Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 18
- 230000002401 inhibitory effect Effects 0.000 abstract description 12
- 208000015181 infectious disease Diseases 0.000 abstract description 11
- 238000002474 experimental method Methods 0.000 abstract description 9
- CKIHZSGJPSDCNC-UHFFFAOYSA-N Quindoxin Chemical class C1=CC=C2N([O-])C=C[N+](=O)C2=C1 CKIHZSGJPSDCNC-UHFFFAOYSA-N 0.000 abstract description 6
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 6
- 230000006870 function Effects 0.000 abstract description 4
- 239000012453 solvate Substances 0.000 abstract description 4
- 230000010076 replication Effects 0.000 abstract description 3
- 150000004677 hydrates Chemical class 0.000 abstract description 2
- 230000003334 potential effect Effects 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 description 46
- 210000000059 tachyzoite Anatomy 0.000 description 33
- 241000223996 Toxoplasma Species 0.000 description 31
- 241000238631 Hexapoda Species 0.000 description 28
- 210000003501 vero cell Anatomy 0.000 description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 19
- 230000035755 proliferation Effects 0.000 description 19
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethyl sulfoxide Natural products CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 16
- 238000000338 in vitro Methods 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 10
- 238000004113 cell culture Methods 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 238000011160 research Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- CUJMCPPBTUATEJ-UHFFFAOYSA-N 1-(3-methyl-4-oxido-1-oxoquinoxalin-1-ium-2-yl)ethanone Chemical compound C1=CC=C2[N+](=O)C(C(=O)C)=C(C)N([O-])C2=C1 CUJMCPPBTUATEJ-UHFFFAOYSA-N 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 235000019441 ethanol Nutrition 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- 244000052769 pathogen Species 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 5
- 239000005090 green fluorescent protein Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 239000012224 working solution Substances 0.000 description 5
- RGHHSNMVTDWUBI-UHFFFAOYSA-N 4-hydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1 RGHHSNMVTDWUBI-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000004660 morphological change Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- IOKWXGMNRWVQHX-VAWYXSNFSA-N (e)-1-(3-methyl-4-oxido-1-oxoquinoxalin-1-ium-2-yl)-3-phenylprop-2-en-1-one Chemical compound O=[N+]1C2=CC=CC=C2N([O-])C(C)=C1C(=O)\C=C\C1=CC=CC=C1 IOKWXGMNRWVQHX-VAWYXSNFSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 3
- TURHTASYUMWZCC-UHFFFAOYSA-N Olaquindox [BAN:INN] Chemical compound C1=CC=C2N([O-])C(C)=C(C(=O)NCCO)[N+](=O)C2=C1 TURHTASYUMWZCC-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 229960004050 aminobenzoic acid Drugs 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 229950010210 olaquindox Drugs 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 229940124530 sulfonamide Drugs 0.000 description 3
- 150000003456 sulfonamides Chemical class 0.000 description 3
- DPJCXCZTLWNFOH-UHFFFAOYSA-N 2-nitroaniline Chemical compound NC1=CC=CC=C1[N+]([O-])=O DPJCXCZTLWNFOH-UHFFFAOYSA-N 0.000 description 2
- ZETIVVHRRQLWFW-UHFFFAOYSA-N 3-nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC=CC(C=O)=C1 ZETIVVHRRQLWFW-UHFFFAOYSA-N 0.000 description 2
- ALNKTVLUDWIWIH-UHFFFAOYSA-N 3a-(5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl)-2,4-dihydro-1h-furo[2,3-b]indol-8b-ol Chemical compound C1C(C(C2)C=C)CCN2C1C12OCCC1(O)C1=CC=CC=C1N2 ALNKTVLUDWIWIH-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241000589893 Brachyspira hyodysenteriae Species 0.000 description 2
- 108010019160 Pancreatin Proteins 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000001938 anti-toxoplasmal effect Effects 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 238000007877 drug screening Methods 0.000 description 2
- 238000002546 full scan Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000003120 macrolide antibiotic agent Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- 230000003071 parasitic effect Effects 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 239000000273 veterinary drug Substances 0.000 description 2
- RXZBMPWDPOLZGW-XMRMVWPWSA-N (E)-roxithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/OCOCCOC)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 RXZBMPWDPOLZGW-XMRMVWPWSA-N 0.000 description 1
- AWBOSXFRPFZLOP-UHFFFAOYSA-N 2,1,3-benzoxadiazole Chemical compound C1=CC=CC2=NON=C21 AWBOSXFRPFZLOP-UHFFFAOYSA-N 0.000 description 1
- ACTOXUHEUCPTEW-BWHGAVFKSA-N 2-[(4r,5s,6s,7r,9r,10r,11e,13e,16r)-6-[(2s,3r,4r,5s,6r)-5-[(2s,4r,5s,6s)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-10-[(2s,5s,6r)-5-(dimethylamino)-6-methyloxan-2-yl]oxy-4-hydroxy-5-methoxy-9,16-dimethyl-2-o Chemical compound O([C@H]1/C=C/C=C/C[C@@H](C)OC(=O)C[C@@H](O)[C@@H]([C@H]([C@@H](CC=O)C[C@H]1C)O[C@H]1[C@@H]([C@H]([C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(O)C2)[C@@H](C)O1)N(C)C)O)OC)[C@@H]1CC[C@H](N(C)C)[C@@H](C)O1 ACTOXUHEUCPTEW-BWHGAVFKSA-N 0.000 description 1
- OKEAMBAZBICIFP-UHFFFAOYSA-N 3-oxido-2,1,3-benzoxadiazol-3-ium Chemical compound C1=CC=CC2=[N+]([O-])ON=C21 OKEAMBAZBICIFP-UHFFFAOYSA-N 0.000 description 1
- BGNGWHSBYQYVRX-UHFFFAOYSA-N 4-(dimethylamino)benzaldehyde Chemical compound CN(C)C1=CC=C(C=O)C=C1 BGNGWHSBYQYVRX-UHFFFAOYSA-N 0.000 description 1
- AVPYQKSLYISFPO-UHFFFAOYSA-N 4-chlorobenzaldehyde Chemical compound ClC1=CC=C(C=O)C=C1 AVPYQKSLYISFPO-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 241000224483 Coccidia Species 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108090000279 Peptidyltransferases Proteins 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 208000005107 Premature Birth Diseases 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- ALNKTVLUDWIWIH-HLQCWHFUSA-N Quinamine Natural products C([C@H]([C@H](C1)C=C)C2)CN1[C@@H]2[C@]12OCC[C@@]1(O)C1=CC=CC=C1N2 ALNKTVLUDWIWIH-HLQCWHFUSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004187 Spiramycin Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 241000504303 Toxoplasma gondii RH Species 0.000 description 1
- 206010057179 Toxoplasma infections Diseases 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000002844 continuous effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 108010014404 dihydrofolate synthetase Proteins 0.000 description 1
- OZRNSSUDZOLUSN-LBPRGKRZSA-N dihydrofolic acid Chemical compound N=1C=2C(=O)NC(N)=NC=2NCC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OZRNSSUDZOLUSN-LBPRGKRZSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 150000002431 hydrogen Chemical group 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 244000000056 intracellular parasite Species 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- 229960005287 lincomycin Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- IHFZUIBTENSHSH-UHFFFAOYSA-N n,n-dimethoxy-1-phenylmethanamine Chemical compound CON(OC)CC1=CC=CC=C1 IHFZUIBTENSHSH-UHFFFAOYSA-N 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 150000003252 quinoxalines Chemical class 0.000 description 1
- 230000011506 response to oxidative stress Effects 0.000 description 1
- 229960005224 roxithromycin Drugs 0.000 description 1
- SMQUZDBALVYZAC-UHFFFAOYSA-N salicylaldehyde Chemical compound OC1=CC=CC=C1C=O SMQUZDBALVYZAC-UHFFFAOYSA-N 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 229960001294 spiramycin Drugs 0.000 description 1
- 229930191512 spiramycin Natural products 0.000 description 1
- 235000019372 spiramycin Nutrition 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 208000002254 stillbirth Diseases 0.000 description 1
- 231100000537 stillbirth Toxicity 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004306 sulfadiazine Drugs 0.000 description 1
- 229960005404 sulfamethoxazole Drugs 0.000 description 1
- GPTONYMQFTZPKC-UHFFFAOYSA-N sulfamethoxydiazine Chemical compound N1=CC(OC)=CN=C1NS(=O)(=O)C1=CC=C(N)C=C1 GPTONYMQFTZPKC-UHFFFAOYSA-N 0.000 description 1
- 229960002229 sulfametoxydiazine Drugs 0.000 description 1
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 206010048282 zoonosis Diseases 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to application of quinoxaline-1, 4-dioxide compounds in resisting Toxoplasma gondii infection, in particular to novel quinoxaline-1, 4-dioxide compounds, especially geometric isomers and pharmaceutically acceptable solvates and/or hydrates thereof, and application of a pharmaceutical composition containing the compounds in resisting Toxoplasma gondii (Toxoplasma gondii) infection. Experiments prove that the compound has the functions of protecting cells infected by Toxoplasma gondii and inhibiting replication and reproduction of Toxoplasma gondii, and has potential effects on resisting Toxoplasma gondii infection.
Description
Technical Field
The invention relates to a novel quinoxaline-1, 4-dioxide compound, in particular to a geometric isomer thereof, a pharmaceutically acceptable solvate and/or hydrate thereof, and a pharmaceutical composition containing the compound, and application of the compound in resisting Toxoplasma gondii (Toxoplasma gondii) infection.
Background
Quinoxaline-1, 4-dioxide compounds (formula I) were originally developed for use as antibacterial agents. In the early research of quinoxaline-1, 4-dioxide compounds, strong and efficient in-vitro activity against Treponema hyodysenteriae (Treponema hyodysenteriae) is widely concerned. To date, the compounds olaquindox, carba and the like are the main drugs for resisting the pathogens. For years, the quinoxaline-1, 4-dioxide compound is still highly valued by people, and a plurality of scholars continuously carry out various structural modifications on the quinoxaline compound, but most structural modifications retain the basic chemical skeleton of the quinoxaline-1, 4-dioxide compound. Therefore, the basic chemical framework of the quinoxaline-1, 4-dioxide compound has very important and irreplaceable functions. Our research is therefore also a search for new biological activities and uses based on this basic chemical framework.
At present, quinoxaline-1, 4-dioxide compounds commonly used in veterinary clinical practice in China comprise quinocetone, mequindox, olaquindox and the like. Mequindox (mequindox) and Quinocetone (QCT) belong to artificially synthesized quinoxaline 1, 4-dioxide drugs, are novel veterinary drugs developed by the Lanzhou veterinary drug research institute of the Chinese academy of agricultural sciences, are mainly used as novel quinoxaline antibacterial growth promoters, and are widely applied to animal growth promotion in the breeding industry in China to improve the conversion rate of animal feed. However, the application of the medicine in resisting Toxoplasma gondii is not reported.
Toxoplasma gondii (academic name: Toxoplasma gondii) is a protozoan of the order Coccidia, also known as Toxoplasma gondii or Toxoplasma gondii, and is a parasitic organism of the genus Toxoplasma. Toxoplasma is a worldwide parasitic protozoa, and its intermediate hosts are extensive, including reptiles, fish, insects, birds, mammals and other animals and humans; the final host is only the cat and the feline. Toxoplasmosis (toxoplasmosis) is a disease caused by toxoplasma which causes serious zoonosis. Toxoplasma infection in early-pregnancy women can lead to abortion, premature birth and even stillbirth, and can also cause newborn deformity and fetal eye complications through placenta. In people with immune deficiency or hypoimmunity (such as AIDS and tumor patients), Toxoplasma gondii can cause serious clinical symptoms (such as Toxoplasma gondii encephalopathy) and even death. In immunocompromised hosts, toxoplasma often forms a chronic infection causing irreversible central nervous system and vision damage. Toxoplasma, a protozoan of an opportunistic intracellular parasite, primarily elicits a cellular immune response in the host.
At present, the therapeutic drugs for toxoplasmosis are mainly sulfonamides, wherein sulfadiazine, sulfamethoxydiazine, sulfamethoxazole and synergist dimethoxybenzylamine and trimethoprim are used more frequently. Different degrees of sulfonamide resistant toxoplasma have been generated clinically today. In addition, macrolide antibiotics such as roxithromycin, spiramycin and azithromycin and lincomycin antibiotics such as clindamycin and milomycin also have effects of preventing and treating toxoplasmosis to different degrees. However, the medicaments have the defects of long treatment time, difficulty in thoroughly killing the insects, easy relapse of animals, large side effect and the like.
The quinoxaline-1, 4-dioxide compound of the invention belongs to quinoxaline compounds, and is different from the existing toxoplasmosis treatment drugs on the market in terms of chemical structure. And the existing research shows that the chemical structure of the sulfonamides is similar to that of p-aminobenzoic acid (PABA), and can compete with the PABA for dihydrofolate synthetase to influence the synthesis of dihydrofolate, so that the growth and the reproduction of bacteria, toxoplasma and the like are inhibited; macrolide antibiotics, which are the general term for a class of antibacterial drugs having a 12-16 carbon lactone ring in their molecular structure, act by inhibiting bacterial protein synthesis by blocking peptidyl transferase activity in the 50s ribosome of the pathogen. The action mechanism of the quinoxaline-1, 4-dioxide compound is still unclear at present, and the existing research shows that the compound can release 1, 4-dioxygen groups on the parent nucleus in a pathogen, so that a large number of free radicals are generated in the pathogen cell, the pathogen generates an oxidative stress reaction, and the oxidative reaction further causes the oxidation of macromolecular substances such as protein, nucleic acid and the like in the pathogen cell to lose activity so as to generate the biological activity of the compound.
Disclosure of Invention
The invention discovers that the quinoxaline-1, 4-dioxide compound (formula I) has the functions of protecting toxoplasma gondii infected cells and inhibiting the replication and reproduction of toxoplasma gondii through creative research, and has potential effect on resisting toxoplasma gondii infection. Further preferably, 2 compounds have remarkable effects and good effects, and can effectively reduce the number of live toxoplasma gondii, reduce cytopathy caused by toxoplasma gondii infection and reduce the level of the number of tachyzoites of the toxoplasma gondii at the concentration of mu g/mL.
Specifically, the invention provides a quinoxaline-1, 4-dioxide compound with a structure shown in a formula I, a geometric isomer thereof, and a pharmaceutically acceptable solvate or hydrate thereof:
wherein R1, R2, R3 may optionally be selected independently from each other from: h (hydrogen), OH (hydroxyl), Cl (chlorine), NO2(nitro), -OCH3(methoxy), -NC2H5(N, N-dimethylamino).
In addition, the invention also relates to a pharmaceutical composition containing the quinoxaline-1, 4-dioxide compound (formula I) and pharmaceutically acceptable solvates or hydrates thereof and a pharmaceutically acceptable carrier. The pharmaceutical composition can be used in various ways, such as oral tablets, capsules, powders, oral liquids, injections and transdermal preparations. Pharmaceutically acceptable carriers include diluents, fillers, disintegrants, wetting agents, lubricants, colorants, flavoring agents, or other conventional additives, according to conventional pharmaceutical practice. Typical pharmaceutically acceptable carriers include, for example, microcrystalline cellulose, starch, cross-linked polyvidones, povidone, polyvinylpyrrolidone, maltitol, citric acid, sodium dodecyl sulfate or magnesium stearate, and the like.
Another aspect of the invention relates to pharmaceutical compositions comprising at least one pharmaceutically acceptable carrier for a compound of the invention. The pharmaceutical composition may be prepared in various forms according to different administration routes.
Also provided is the use of a compound of formula (I) for combating Toxoplasma gondii (Toxoplasma gondii) infection in order to protect an animal from Toxoplasma attack.
Drawings
FIG. 1 is an in vitro observation of the proliferation inhibition of Toxoplasma gondii tachyzoite by drug screening, and the proliferation status of Toxoplasma gondii after 48h of partial drug action under a fluorescence microscope;
FIG. 2 is a graph showing the proliferation state of Toxoplasma gondii after DL-QCT (No. 4) acts on Toxoplasma gondii tachyzoite in vitro and DL-QCT acts for 48 hours under a fluorescence microscope;
FIG. 3 is a graph showing the proliferation state of Toxoplasma gondii in vitro by JQ-QCT (No. 8) on Toxoplasma gondii tachyzoite and 48h after JQ-QCT action under a fluorescence microscope
Detailed Description
The following examples are illustrative of preferred embodiments of the present invention and are not to be construed as limiting the invention in any way.
The starting materials or reagents used in the examples are, unless otherwise specified, commercially available.
The experimental procedures, in which specific conditions are not noted in the following examples, are generally carried out under conventional conditions or conditions recommended by the manufacturers.
The Toxoplasma gondii standard strength strain (RH strain) used in the embodiment has biological characteristics representing the characteristics of Toxoplasma gondii in China.
In the examples, the lytic agent is dimethyl sulfoxide, which has the function of increasing solubility and permeability of the drug and has no toxic effect on experimental cells or animals.
The structural formula, the name or the number of the quinoxaline-1, 4-dioxide compound (formula I) related in each embodiment of the invention are shown in the table 1.
TABLE 1 substituent, name code or numbering of quinoxaline-1, 4-dioxide compound (formula I)
Example 1: preparation of quinoxaline-1, 4-dioxide compound for inhibiting toxoplasma gondii proliferation in Vero cells
1. Synthesis of benzofurazan monoxide
In a 250ml four-neck flask, about 0.2mol of o-nitroaniline (molecular weight: 138), 0.28mol of KOH are dissolved in 250ml of 95% ethanol, the mixture is stirred until the o-nitroaniline is dissolved, 250ml of NaClO solution is dropwise added under ice bath, yellow precipitate is gradually precipitated, the reaction is monitored by TLC, and a developing agent PE: EA (petroleum ether: ethyl acetate) ═ 5: 1. After 8h, after the reaction is finished, adding water for filtration, washing with water to obtain yellow precipitate, recrystallizing with 70% ethanol to obtain 22.64g of product with the yield of 82.35%, wherein the reaction formula isElectrospray full-scan mass spectrometry, excimer [ M + H ]]+ m/z is 137. mp: 68.8-70.5 ℃.
2. Synthesis of 2-acetyl-3-methylquinoxaline-1, 4-dioxide (mequindox, MAQO)
Adding 0.05mol of benzofurazan into a 250ml four-mouth bottle, then adding 0.12mol of acetylacetone (molecular weight: 100), stirring at room temperature until the mixture is dissolved, carrying out water bath at room temperature, dropwise adding 22ml of triethylamine (molecular weight 101.19), heating to 40-45 ℃ for several minutes, stirring to gradually separate out yellow crystals (or standing until the mixture is naturally cooled and completely reacts for 10 hours to obtain a large amount of yellow crystals), monitoring the reaction by TLC, wherein a developing agent is PE: EA (petroleum ether: ethyl acetate) ═ 1: 1, carrying out suction filtration, washing by a small amount of ethanol, recrystallizing by 70% of ethanol to obtain 6.5g of product, the yield is 60%, and the reaction formula is thatElectrospray full-scan mass spectrometry, excimer [ M + H ]]+ m/z is 219. Namely mequindox (molecular weight: 218.21).
3. Synthesis of Compounds 1-9
In a 250ml four-necked flask,respectively heating and stirring 15-25 mmol of benzaldehyde, p-hydroxybenzaldehyde, o-hydroxybenzaldehyde, m-nitrobenzaldehyde, p-methoxybenzaldehyde, p-chlorobenzaldehyde, p-dimethylaminobenzaldehyde and the like, dissolving the above materials in 20-50 ml of absolute ethyl alcohol or methanol, then respectively adding 2.2g (about 10mmol) of 2-acetyl-3-methyl quinoxaline-1, 4-dioxide at 50-55 ℃, stirring until the mixture is dissolved, controlling the temperature to be 50-55 ℃, dropwise adding 2-10 ml of diethylamine, stirring at 50-55 ℃ for overnight after the addition is finished, gradually changing the color to yellow, brown or reddish brown and gradually precipitating with precipitates, carrying out monitoring and tracking reaction by Thin Layer Chromatography (TLC), adding water, stirring, filtering, washing with a small amount of ethanol to remove excessive p-hydroxybenzaldehyde, Recrystallizing reaction substrates such as m-nitrobenzaldehyde, solvents and impurities with 95% ethanol, and naturally drying to obtain compounds 1-9 respectively, namely: p-hydroxyquinocetone (DQ-QCT), o-hydroxyquinocetone (LQ-QCT), m-hydroxyquinocetone (JQ-QCT), m-nitroquinocetone (JX-QCT), p-nitroquinocetone (DX-QCT), p-methoxyquinocetone (DKY-QCT), p-chloroquinocetone (DL-QCT) and p-dimethylaminoquinocetone (DJA-QCT), wherein the reaction formula isWherein R is hydrogen, p-hydroxyl, o-hydroxyl, m-nitro, p-methoxyl, p-chloro and p-dimethylamino.
4. Identification of Compounds 1-9
The synthesized compounds respectively take DMSO as a solvent, perform hydrogen spectrum analysis on a Bruker 400MHz type nuclear magnetic resonance instrument, perform infrared spectrum analysis in a KBr tablet sample preparation mode, perform ultraviolet spectrum scanning analysis by taking chromatographic grade methanol as a solvent, and perform electrospray ionization source (ESI) mass spectrum analysis by taking acetonitrile as a solvent. Meanwhile, the content of each drug is measured by adopting a high performance liquid chromatography, and the content of all tested compounds is ensured to be more than 98%.
Example 2: activity identification for inhibiting toxoplasma gondii proliferation in Vero cells
The implementation steps are as follows:
1. preparation of a drug stock solution:
50mg of each of the above drugs (quinoxaline-1, 4-dioxide compound (formula I), No. 1 to 9) was dissolved in 10mL of dimethyl sulfoxide (DMSO) to obtain a stock solution of 5mg/mL, and the stock solution was stored at 4 ℃. The working solution of the drug is diluted by 10 percent of FBS DMEM medium before use, and is subjected to filtration sterilization, so that the final concentration of the drug contains DMSO (dimethyl sulfoxide) not more than 1.0 percent, and the working solution of the drug is used for toxicity test of Vero cells and inhibitory effect test of Toxoplasma gondii proliferation.
2. Vero cells:
vero cells were kept in an animal parasitology-intensive open laboratory in Shanghai veterinary research institute of agricultural rural area, China academy of agricultural sciences. At 37 ℃ with 5% CO2Culturing in an incubator, culturing in 10% FBS DMEM medium, digesting with pancreatin, transferring 2-3 generations until cells are stable, and counting with a cell counter and adjusting the number for later use. Fetal bovine serum, DMEM medium, diabody (penicillin, streptomycin antibiotic) were purchased from Gibco, usa, and 24-well cell culture plates and cell culture bottles were purchased from Corning, usa.
3. Toxoplasma tachyzoite:
toxoplasma RH/GFP strain tachyzoites were given by the university of livestock products, national zone of Japan, and were subcultured in Vero cells. The Toxoplasma gondii RH/GFP strain tachyzoite is a worm body expressing green fluorescent protein, and because the green fluorescent protein gene is transfected into the worm body and integrated into the genome of the worm body, the Toxoplasma gondii can be expressed along with the replication of the worm body, and the Toxoplasma gondii strain tachyzoite is not lost after passage, so that the Toxoplasma gondii strain tachyzoite is easier to observe after infection.
4. Cytotoxicity test:
the MTT method was used to divide the experiment into three groups, a blank control group (no Vero cells and drug added), a test control group (Vero cells only added), and a drug test group (Vero cells added and drug at various concentrations). Taking 96-well plate, adding 10% FBS DMEM medium (DMSO is not more than 1.0%) containing drugs with final concentration of 50, 20, 10, 5, 2.5, 1.0 μ g/mL when the cell growth is more than 80%, and adding 5% CO at 37 deg.C2After 24 hours of culture in an incubator, 20 mu L of MTT working solution with the concentration of 5mg/mL is added into each hole, after 4 hours, the supernatant is discarded, 200 mu L of DMSO is added for 0.5 hour,the microplate reader reads the OD at a wavelength of 570nm (average of 5 replicate wells). The drug concentration in which the cell survival rate is higher than 80% is selected for the research of the inhibition effect of the proliferation of the anti-toxoplasma tachyzoite.
5. And (3) worm body culture:
culturing Vero cell and toxoplasma in 5% CO237 ℃ CO2An incubator. 8% fetal bovine serum and double antibody are added into the culture solution. When the cells grow to be more than 80% of confluency, the cells are digested by pancreatin, collected and passed to a new cell culture bottle, and after 48 hours of culture, the growth condition of the cells is observed under a mirror. The worm bodies are inoculated to cells paved in a 70% cell culture bottle, after the cells are cultured for 72 hours, the worm bodies and the cells are scraped by a cell scraper, a needle of a 26G (0.45#) syringe repeatedly sucks and blows 3 times to lyse the cells, a 5 mu m needle filter filters and removes cell debris to purify the worm bodies, the worm bodies are centrifuged at 2000rpm for 10min, the worm body sediment is resuspended by a DMEM medium containing 10% FBS, and the green fluorescent spot worm bodies are observed and counted by a fluorescence microscope.
6. Toxoplasma gondii proliferation resistance test:
vero cells were passaged into 24-well cell culture plates, 800 Vero cells per well in a volume of 1mL, and after 24h of culture, 2000 purified RH/GFP Toxoplasma gondii tachyzoites in a volume of 100. mu.L were added per well. After the two are cultured for 2h, the culture solution in each well is aspirated, and the Vero extracellular tachyzoites are removed by washing twice with the cell culture solution. Adding prepared drug working solution, and setting drug group, positive control group (PBS group) and cell blank control group. The drug groups were infected with somatic insect cells and given the corresponding drugs, with final concentrations of the drugs selected at 12, 3 and 0.6 μ g/mL (DMSO not more than 1.0%): the positive control group is infected worm somatic cells which are not dosed but are given PBS with corresponding volume; the cell blank group was a cell culture that was not administered either drug or somatic infection. Each experimental group was set up in 3 duplicate wells and the experiment was repeated three times. Observing the proliferation condition and morphological change of the toxoplasma gondii tachyzoite at 48h and 72h after administration under a fluorescence microscope, counting the number of live insects according to the green fluorescence points (one fluorescence point represents one insect body because the insect body proliferates in an exponential mode, and one fluorescence point is counted as one insect body during counting), and analyzing the reduction rate of the drug to the toxoplasma gondii:
the reduction rate is (average infection number of positive control group polypide-average infection number of drug group polypide) ÷ average infection number of positive control group polypide is multiplied by 100%
7. Statistical analysis:
the counts were expressed as mean. + -. standard deviation (ā. + -.s), the variances were compared and a t-test was performed, and P < 0.05 indicated that the differences were statistically significant.
8. Results
Cytotoxicity
The MTT method detects that each drug has certain toxicity to Vero cells in a soluble range. The drug concentrations of the drugs 1 to 9 for the cell viability of more than 80% are mostly about 10 mug/mL. Therefore, 12. mu.g/mL was selected as the highest drug concentration for the anti-Toxoplasma test to perform the efficacy test.
In vitro observation of drug screening for inhibition of toxoplasma tachyzoite proliferation
After administration for 48h and 72h, the proliferation and morphological change of toxoplasma tachyzoites in each experimental group were observed by an inverted fluorescence microscope. After 48h, the change is obvious, and the positive control group (PBS group) Toxoplasma gondii tachyzoite can be seen under a fluorescence microscope to proliferate in Vero cells in a large amount, and the shape is approximately normal. The PBS group toxoplasma tachyzoites proliferate actively and are represented as a plurality of fluorescent spots; compared with the prior art, the Toxoplasma gondii tachyzoite in Vero cells can be seen under each low-concentration drug group mirror, and the Toxoplasma gondii tachyzoite has normal shape and good activity. But with the increase of the concentration of the medicine, the toxoplasma tachyzoite density intensity of each administration group is weakened and reduced to different degrees; meanwhile, a phenomenon of drug crystal precipitation (mainly quinoxaline mother nucleus dideoxy compounds with numbers 1-9) is seen in certain high-concentration drug groups, which indicates that the drugs have poor solubility in a toxoplasma culture environment, and further observation shows that the compounds have poor growth inhibition effect on the toxoplasma. 72h further observation shows that in the drug group with the inhibiting effect in 48h observation, the toxoplasma tachyzoite density intensity is further weakened, and a large number of dead insect bodies without activity appear along with the continuous effect of the drugs and the consumption of nutrient substances. The results are shown in FIG. 1.
Drug counts for Toxoplasma inhibition
The live insect counts were performed on each drug group (compounds numbered 1-9 and 2-methylquinoxaline-1, 4-dioxy, olaquindox) with significant inhibitory effect, and the results are shown in table 2. And 48h, compared with a positive control group, the number of the live insects in a plurality of drug groups is reduced, and the number of the live insects is significant along with the increase of the concentration. Wherein, compared with other medicines, the number of the live insects in the medicine groups of the numbers 4 and 8 is obviously reduced at the medicine dose of 0.6 mu g/mL. The drug doses of numbers 1,4 and 8 are all significantly reduced above 3 mug/mL. And 72h, the number of live insects in each experimental group is obviously reduced, and a large number of dead insects appear. The drugs numbered 1,4 and 8 are indicated to be better able to inhibit toxoplasma tachyzoite proliferation in vitro at a certain dose for continued validation studies.
TABLE 2 Toxoplasma results in Vero cells against each of the screened drugs
Note: each group was provided with 3 replicates, 3 replicates. P < 0.05 compared to PBS group; denotes P < 0.01.
And (4) conclusion:
the experiments show that the synthesized quinoxaline-1, 4-dioxide compound (formula I, number 1-9) and quinamine alcohol have certain effect of inhibiting the reproduction of toxoplasma gondii in vitro, but the parent nucleus deoxyribose compound of the quinoxaline-1, 4-dioxide compound (formula I, number 1-9) has poor solubility and almost no insect resistance effect. The mother nucleus 1, 4-dioxy of the quinoxaline-1, 4-dioxy compound is an important functional group for resisting toxoplasma gondii, and the effect of resisting toxoplasma gondii can be increased through structural modification, so that the DL-QCT and JQ-QCT compounds are screened to have better toxoplasma gondii resisting effect, but the effect of the DL-QCT and JQ-QCT compounds needs to be further researched and confirmed.
Example 3: experiment for inhibiting toxoplasma gondii proliferation in vitro by using DL-QCT and JQ-QCT
The experimental preparation and the specific operation were as described in example 2, except that the relevant experiments were performed for DL-QCT, JQ-QCT (numbers 4, 8, respectively).
1. Toxoplasma gondii proliferation resistance test:
vero cells were passaged into 24-well cell culture plates, 800 Vero cells per well in a volume of 1mL, and after 24h of culture, 2000 purified RH/GFP Toxoplasma gondii tachyzoites in a volume of 100. mu.L were added per well. After the two are cultured for 2h, the culture solution in each well is aspirated, and the Vero extracellular tachyzoites are removed by washing twice with the cell culture solution. Adding prepared medicinal working solution, and setting administration group and blank control group (PBS group). Selecting drugs with final concentrations of 0.5, 1, 2 and 4 mug/mL (DMSO is not more than 1.0 percent) respectively; the blank control group was given only the corresponding volume of PBS. Each experimental group was set up in 3 duplicate wells and the experiment was repeated three times. Observing the proliferation condition and the morphological change of the toxoplasma tachyzoite at 48h and 72h after the administration under a fluorescence microscope, counting the number of live insects according to green fluorescence points (one fluorescence point represents one insect body because the insect body proliferates in an exponential mode, and one fluorescence point is counted as one insect body during counting), and analyzing the insect reduction rate of the drug to the toxoplasma:
the reduction rate is (average infection number of control polypide-average infection number of test polypide) ÷ average infection number of control polypide multiplied by 100%
2. Statistical analysis:
the counts were expressed as mean. + -. standard deviation (ā. + -.s), the variances were compared and a t-test was performed, and P < 0.05 indicated that the differences were statistically significant.
3. Results
In vitro observation of Toxoplasma tachyzoite proliferation of each group
After administration for 48h and 72h, the proliferation and morphological change of toxoplasma tachyzoites in each experimental group were observed by an inverted fluorescence microscope. After 48h, the change is obvious, the toxoplasma tachyzoite of the blank control group is greatly increased in Vero cells under a fluorescence microscope, and the shape is approximately normal. The toxoplasma tachyzoite in the blank control group proliferates actively and is represented as a plurality of fluorescent spots; compared with the Vero cell, toxoplasma tachyzoite in Vero cells can be seen in each drug group with the concentration of 0.5 mu g/mL under a microscope, and the Vero cell is normal in shape and good in activity. But with the increase of the concentration of the medicine, the density and the intensity of the toxoplasma tachyzoite of each administration group are weakened and reduced to different degrees; among them, the effect is most remarkable in DL-QCT. And 72h, the density and the strength of toxoplasma tachyzoites of each experimental group are further weakened, and a large number of dead insects without activity appear along with the continuous action of the medicine and the consumption of nutrient substances. The results are shown in FIGS. 2 and 3.
The drug count the inhibitory effect on Toxoplasma gondii
The number of live insects in each drug experiment group was counted and shown in Table 3. 48h, compared with the non-administration group, the number of the live insects in each administration group is reduced, and the live insects are significant along with the increase of the concentration. Wherein, the number of the living insects in the group administered with the DL-QCT medicament is remarkably reduced by more than 2 mug/mL of medicament dose. And 72h, the number of live insects in each experimental group is obviously reduced, and a large number of dead insects appear. It is shown that both the drugs Nos. 4 and 8 are better able to inhibit Toxoplasma tachyzoite proliferation in vitro at a certain dosage.
TABLE 3 counting results of DL-QCT, JQ-QCT against Toxoplasma gondii in vitro
Note: each group was provided with 3 replicates, 3 replicates. P < 0.05 compared to PBS group; denotes P < 0.01.
And (4) conclusion:
through repeated verification tests of in vitro Toxoplasma gondii propagation, the DL-QCT and DQ-QCT have good effects of inhibiting Toxoplasma gondii propagation in vitro, but the insect-resistant effect of the DL-QCT is optimal.
Claims (2)
1. The application of the quinoxaline-1, 4-dioxide compound with the general formula I in preparing the medicine for resisting Toxoplasma gondii infection is provided, the quinoxaline-1, 4-dioxide compound with the general formula I can effectively inhibit the number of invading cells of Toxoplasma gondii (Toxoplasma gondii) and effectively reduce the cytopathic capability of Toxoplasma gondii, thereby having the effect of resisting Toxoplasma gondii infection,
wherein,
r1 is H (hydrogen), R2 is H (hydrogen), R3 is Cl (chloro);
r1 is H (hydrogen), R2 is OH (hydroxyl), and R3 is H (hydrogen).
2. The use of claim 1, wherein the medicament further comprises a pharmaceutically acceptable carrier.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910400204.7A CN110269859B (en) | 2019-05-07 | 2019-05-07 | Application of quinoxaline-1, 4-dioxide compound in resisting toxoplasma gondii infection |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910400204.7A CN110269859B (en) | 2019-05-07 | 2019-05-07 | Application of quinoxaline-1, 4-dioxide compound in resisting toxoplasma gondii infection |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110269859A CN110269859A (en) | 2019-09-24 |
CN110269859B true CN110269859B (en) | 2022-05-17 |
Family
ID=67959926
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910400204.7A Active CN110269859B (en) | 2019-05-07 | 2019-05-07 | Application of quinoxaline-1, 4-dioxide compound in resisting toxoplasma gondii infection |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110269859B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114621195B (en) * | 2022-03-28 | 2023-07-11 | 华中农业大学 | quinoxaline-N 1 ,N 4 -dioxide derivatives |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102372678A (en) * | 2010-08-24 | 2012-03-14 | 许吉冲 | Feed additive quinocetone and preparation method thereof |
CN103145631A (en) * | 2013-03-18 | 2013-06-12 | 广州英赛特生物技术有限公司 | Antibacterial derivative of quinoxaline-1,4-dioxide and application in animal production thereof |
CN104447587A (en) * | 2013-03-18 | 2015-03-25 | 广州英赛特生物技术有限公司 | Application of quinoxaline-1,4-dioxide in animal production |
-
2019
- 2019-05-07 CN CN201910400204.7A patent/CN110269859B/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102372678A (en) * | 2010-08-24 | 2012-03-14 | 许吉冲 | Feed additive quinocetone and preparation method thereof |
CN103145631A (en) * | 2013-03-18 | 2013-06-12 | 广州英赛特生物技术有限公司 | Antibacterial derivative of quinoxaline-1,4-dioxide and application in animal production thereof |
CN104447587A (en) * | 2013-03-18 | 2015-03-25 | 广州英赛特生物技术有限公司 | Application of quinoxaline-1,4-dioxide in animal production |
Non-Patent Citations (2)
Title |
---|
In vitro antimicrobial activities of animal-used quinoxaline 1,4-di-N-oxides against mycobacteria, mycoplasma and fungi;Yan,zhao等;《BMC VETERINARY RESEARCH》;20160906;第12卷(第186期);1-13 * |
喹烯酮体外细胞毒性机制解析;张可煜;《中国优秀博硕士学位论文数据库(博士) 农业科学辑》;20140115;E050-9 * |
Also Published As
Publication number | Publication date |
---|---|
CN110269859A (en) | 2019-09-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11542257B2 (en) | Arylnaphthalene compounds as vacuolar-ATPase inhibitors and the use thereof | |
JP2008505937A (en) | Indoleamine 2,3-dioxygenase (IDO) inhibitor | |
JP2004537561A (en) | Use of stilbene compounds in the manufacture of a medicament for the prevention and treatment of diabetes or a retrovirus-related disease | |
US11725006B2 (en) | Hydrophilic berberine-type derivative and application thereof in preparing drug | |
CN105616400A (en) | Use of arctigenin carbamate derivatives in preparation of drug for treating Alzheimer disease | |
US11208427B2 (en) | Dicaffeoyl spermidine derivative glycosides and use thereof | |
CN110269859B (en) | Application of quinoxaline-1, 4-dioxide compound in resisting toxoplasma gondii infection | |
KR102055176B1 (en) | Kinase inhibitors for the treatment of cancer | |
CN109810108B (en) | 2, 8-diaza-spiro- [4,5] -decane pyrimidine-hydroxamic acid compound and application thereof | |
CN111303055A (en) | Quinazoline derivative and preparation method and application thereof | |
CN109730999B (en) | Application of thiazole benzamide derivative in preparation of anti-osteoporosis and anti-osteoarthritis medicines | |
WO2002066046A1 (en) | Cancer therapeutic agent comprising thiopeptide with multiple thiazole rings | |
US20210230149A1 (en) | Arylnaphthalene compounds as vacuolar-atpase inhibitors and the use thereof | |
CN103635088B (en) | Meter Ge La Statins (Migrastatins) and its purposes | |
KR101457637B1 (en) | A dihydropyrazolecarbothioamide derivative, Method of preparing the same, and anti-cancer agent comprising the same | |
KR101114629B1 (en) | Antileishmanial compound and antileishmanial drug | |
RU2454232C2 (en) | Application of triindolyl methane derivatives as anticancer drugs | |
KR100956576B1 (en) | Composition for protecting hearing cells comprising Epicatechin | |
CN110981888A (en) | N-aryl dithiopyrryl ketonuria and amino ester derivatives, preparation and application thereof | |
KR101629558B1 (en) | A Naphthochalcone and use of the same as anticancer drug | |
JP2021116291A (en) | Pharmaceutical composition containing 2,4-diamino-6,7-dimethoxy quinazoline derivative as an active ingredient, and 2,4-diamino-6,7-dimethoxy quinazoline derivative having specific structure | |
JP3740284B2 (en) | Novel compound having antimalarial activity or salt thereof | |
JP2781073B2 (en) | Novel quinoline derivative and anticancer drug effect enhancer containing the same as active ingredient | |
CN101230015A (en) | Substituted cinnamic acid derivatives containing amine substituent group and expression purification cytotoxicity thereof | |
Prinsloo | Synthesis and biological activity of novel bisquinazolinone derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |